CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Iovance Reports 24.6% Response Rate for Lifileucel in Lung Cancer Trial

By Public Technologies
  • Iovance Biotherapeutics reported updated Phase 2 results showing lifileucel’s activity remained consistent with earlier findings in previously treated non-squamous metastatic lung cancer.
  • A retrospective analysis showed stronger responses in a biomarker-selected subgroup, supporting a targeted development strategy that requires prospective evaluation.
  • The biomarker-enriched POSITILITY cohort will begin enrollment in November 2026, targeting a potential registration pathway subject to FDA feedback.
  • A supplemental biologics license application for lifileucel in non-squamous metastatic non-small-cell lung cancer remains planned for 2027.
  • The frontline OPTILISM trial is scheduled to begin in 2027, supported by encouraging responses to lifileucel with pembrolizumab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855859) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk